Merck’s announced in late November that it would acquire California-based Imago. Under the deal, Merck will add Imago’s lead drug candidate, bomedemstat, to its pipeline. Bomedemstat is in clinical trials for the treatment of myelofibrosis (a rare form of bone-marrow blood cancer) and other diseases.
“This acquisition of Imago augments our pipeline and strengthens our presence in the growing field of hematology,” Merck CEO Rob Davis previously said in a statement.
Imago will become a wholly owned subsidiary of Merck and the common stock of Imago will no longer be listed or traded on the Nasdaq Global Market.